Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Sells 5,000 Shares of Stock


Share on StockTwits

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Greef Roderick De sold 5,000 shares of the firm’s stock in a transaction dated Thursday, April 15th. The stock was sold at an average price of $33.69, for a total transaction of $168,450.00. Following the sale, the chief financial officer now owns 189,538 shares of the company’s stock, valued at approximately $6,385,535.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Greef Roderick De also recently made the following trade(s):

  • On Tuesday, April 13th, Greef Roderick De sold 10,919 shares of BioLife Solutions stock. The shares were sold at an average price of $35.08, for a total transaction of $383,038.52.
  • On Thursday, April 1st, Greef Roderick De sold 3,855 shares of BioLife Solutions stock. The stock was sold at an average price of $36.53, for a total transaction of $140,823.15.
  • On Friday, March 26th, Greef Roderick De sold 2,893 shares of BioLife Solutions stock. The shares were sold at an average price of $35.01, for a total value of $101,283.93.
  • On Friday, February 19th, Greef Roderick De sold 4,509 shares of BioLife Solutions stock. The shares were sold at an average price of $40.76, for a total value of $183,786.84.
  • On Wednesday, February 17th, Greef Roderick De sold 4,424 shares of BioLife Solutions stock. The stock was sold at an average price of $41.55, for a total value of $183,817.20.

NASDAQ:BLFS opened at $33.70 on Friday. The firm has a market capitalization of $1.13 billion, a PE ratio of -46.16, a PEG ratio of 50.41 and a beta of 1.55. The stock’s fifty day moving average is $37.07 and its 200 day moving average is $36.68. BioLife Solutions, Inc. has a fifty-two week low of $9.93 and a fifty-two week high of $47.97.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Sunday, March 21st. The medical equipment provider reported ($0.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.04). The company had revenue of $14.73 million during the quarter, compared to the consensus estimate of $13.43 million. BioLife Solutions had a return on equity of 0.53% and a net margin of 12.67%. As a group, analysts anticipate that BioLife Solutions, Inc. will post 0.01 earnings per share for the current fiscal year.

Several research firms have recently commented on BLFS. Stephens upped their price target on shares of BioLife Solutions from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Tuesday, March 23rd. KeyCorp upped their target price on shares of BioLife Solutions from $40.00 to $50.00 and gave the stock an “overweight” rating in a report on Monday, March 29th. Zacks Investment Research raised BioLife Solutions from a “sell” rating to a “hold” rating in a research note on Wednesday, January 6th. Maxim Group lifted their target price on BioLife Solutions from $40.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, March 23rd. Finally, Benchmark raised shares of BioLife Solutions from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a report on Monday, March 29th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $45.10.

A number of large investors have recently made changes to their positions in BLFS. BlackRock Inc. lifted its holdings in shares of BioLife Solutions by 10.9% in the 4th quarter. BlackRock Inc. now owns 1,232,671 shares of the medical equipment provider’s stock worth $49,172,000 after buying an additional 121,334 shares during the period. Tower House Partners LLP bought a new position in BioLife Solutions during the 4th quarter worth about $18,872,000. Jennison Associates LLC bought a new stake in shares of BioLife Solutions in the 4th quarter valued at about $17,934,000. Northern Trust Corp lifted its position in shares of BioLife Solutions by 0.4% in the 4th quarter. Northern Trust Corp now owns 260,536 shares of the medical equipment provider’s stock worth $10,392,000 after purchasing an additional 1,121 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in BioLife Solutions by 86.6% during the fourth quarter. JPMorgan Chase & Co. now owns 222,521 shares of the medical equipment provider’s stock valued at $8,876,000 after buying an additional 103,276 shares during the period. 67.66% of the stock is currently owned by institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools for the cell and gene therapy industry in North America, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Read More: Most Active Stocks

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.